Anastrozole Effects in Men
Anastrozole is NOT FDA-approved for use in men and carries significant risks, particularly bone loss, despite its off-label use for male infertility and hypogonadism. 1
FDA-Approved Use and Critical Warning
Anastrozole is FDA-approved only for postmenopausal women with breast cancer. The drug label explicitly states it "does not work in women with breast cancer who have not gone through menopause (premenopausal women)" and warns against use in pregnancy 1. There is no FDA approval for male use.
Off-Label Use in Men: Clinical Context
Despite lack of FDA approval, anastrozole is used off-label in men for two primary indications:
1. Male Infertility with Abnormal Testosterone-to-Estradiol Ratio
The 2025 EAU guidelines acknowledge that aromatase inhibitors (including anastrozole) can improve hormonal and semen parameters in infertile men, though they emphasize the need for prospective randomized controlled trials 2. The mechanism involves:
- Blocking estrogen production by inhibiting aromatase enzyme
- Reducing negative feedback on the hypothalamus
- Increasing GnRH pulses and FSH production
- Potentially improving spermatogenesis 2
Evidence shows: Anastrozole significantly increases sperm concentration, total sperm count, LH, FSH, and testosterone levels while reducing estradiol 3. However, the quality of supporting studies remains low 2.
2. Elevated Estradiol During Testosterone Therapy
In men on testosterone replacement therapy (TRT), anastrozole 0.5 mg three times weekly effectively reduces elevated estradiol levels (median reduction from 65 to 22 pg/mL) without compromising testosterone levels 4. Only 2.6-3% of men on TRT require this intervention 4.
Serious Risks and Adverse Effects
Bone Health: The Primary Concern
The most significant risk is bone mineral density (BMD) loss. In a 1-year randomized controlled trial of older men with low testosterone:
- PA spine BMD decreased from 1.121 to 1.102 g/cm² in the anastrozole group
- Placebo group showed BMD increase from 1.180 to 1.189 g/cm²
- The difference was statistically significant (P = 0.0014) 5
Critical finding: Aromatase inhibition does NOT improve skeletal health in aging men with low testosterone levels 5. This contradicts the theoretical benefit of increased testosterone, demonstrating that estrogen suppression dominates the skeletal effect.
Cardiovascular Considerations
Short-term studies (12 weeks) show anastrozole does NOT adversely affect:
- Lipid profiles
- Inflammatory markers (CRP, IL-6)
- Adhesion molecules (ICAM-1, VCAM-1)
- Insulin sensitivity 6
However, the 2025 EAU guidelines list "drug-induced aromatase activity blockade" as a recognized cause of hypogonadism 7, suggesting long-term concerns.
Other Documented Side Effects
Based on FDA labeling (from female studies) and male research:
- Bone fractures (spine, hip, wrist) 1
- Elevated cholesterol 1
- Liver inflammation and dysfunction 1
- Skin reactions (lesions, ulcers, blisters) 1
- Joint pain and arthritis 1
- Hot flashes 1
Clinical Decision Algorithm
For male infertility:
- Consider only if T/E2 ratio is abnormal
- Use lowest effective dose
- Monitor bone density if treatment exceeds 12 weeks
- Recognize evidence quality is low 2
For elevated estradiol on TRT:
- Initiate only if E2 >60 pg/mL (regardless of symptoms) OR E2 40-60 pg/mL with symptoms 4
- Dose: 0.5 mg three times weekly 4
- Monitor E2, testosterone, and bone density
- Consider discontinuing 2-7 days before assisted reproduction procedures 3
Contraindications:
- Do NOT use with tamoxifen (reduces anastrozole efficacy) 1
- Do NOT use with estrogen-containing medications 1
- Avoid in men with pre-existing osteoporosis 1
Critical Pitfall
The most common error is failing to monitor bone health. While short-term studies (12 weeks) showed no bone turnover marker changes 8, longer-term use (1 year) demonstrated clear BMD loss 5. Baseline and serial DEXA scans are mandatory for any man on anastrozole beyond 3 months.